Development and evaluation of a novel anti-colorectal cancer monoclonal antibody, WL5

Biochemical and Biophysical Research Communications

Volumn 432, Issue 2, 2013, Pages 370-377

  Liu, Jin ^a   Di, Guohu ^a   Wu, Chu Tse ^a,c   Hu, Xianwen ^b   Duan, Haifeng ^c  

^a TIANJIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Antitumor activity; CEACAM1; Colorectal cancer; Monoclonal antibody; Specific antigen

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; DOXORUBICIN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; WL5 ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARDIOMYOPATHY; CELL MEDIATED CYTOTOXICITY; CELL STRAIN HT29; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEUKOCYTE COUNT; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE MICROARRAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYBRIDOMAS; MALE; MICE; MICE, INBRED BALB C; TUMOR MARKERS, BIOLOGICAL;

EID: 84875233700     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.089     Document Type: Article

References (24)

1. Ganz P.A. Survivorship: adult cancer survivors. Prim. Care 2009, 36:721-741.
2. Siegel R., Desantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62:220-241.
3. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
4. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
5. Maisonneuve P., Botteri E., Lowenfels A.B. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. Gastroenterology 2008, 135:710. author reply 710-711.
6. Creeden J., Junker F., Vogel-Ziebolz S., Rex D. Serum tests for colorectal cancer screening. Mol. Diagn. Ther. 2011, 15:129-141.
7. Martin E.W., Kibbey W.E., DiVecchia L., Anderson G., Catalano P., Minton J.P. Carcinoembryonic antigen: clinical and historical aspects. Cancer 1976, 37:62-81.
8. Zhang C. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol. Biol. 2012, 901:117-135.
9. Galluzzi L., Vacchelli E., Fridman W.H., Galon J., Sautes-Fridman C., Tartour E., Zucman-Rossi J., Zitvogel L., Kroemer G. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2012, 1:28-37.
10. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
11. Dougan M., Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 2009, 27:83-117.
12. Weiner L.M. Fully human therapeutic monoclonal antibodies. J. Immunother. 2006, 29:1-9.
13. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., DeBlanc R.L., Gearing R.P., Bovee T.D., Siegall C.B., Francisco J.A., Wahl A.F., Meyer D.L., Senter P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21:778-784.
14. Sievers E.L., Appelbaum F.R., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., Shannon-Dorcy K., Berger M.S., Bernstein I.D. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93:3678-3684.
15. Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol. 2006, 6:433-446.
16. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin. Chem. 2001, 47:624-630.
17. Fletcher R.H. Carcinoembryonic antigen. Ann. Intern. Med. 1986, 104:66-73.
18. Gatto B. Monoclonal antibodies in cancer therapy. Curr. Med. Chem. Anticancer Agents 2004, 4:411-414.
19. Luo W., Tapolsky M., Earley K., Wood C.G., Wilson D.R., Logothetis C.J., Lin S.H. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther. 1999, 6:313.
20. Moh M.C., Shen S. The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adh. Migr. 2009, 3:334-336.
21. Kang W.Y., Chen W.T., Wu M.T., Chai C.Y. The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int. J. Colorectal Dis. 2007, 22:869-874.
22. Ieda J., Yokoyama S., Tamura K., Takifuji K., Hotta T., Matsuda K., Oku Y., Nasu T., Kiriyama S., Yamamoto N., Nakamura Y., Shively J.E., Yamaue H. Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int. J. Cancer 2011, 129:1351-1361.
23. Thom I., Schult-Kronefeld O., Burkholder I., Schuch G., Andritzky B., Kastendieck H., Edler L., Wagener C., Bokemeyer C., Schumacher U., Laack E. Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res. 2009, 29:249-254.
24. Arabzadeh A., Chan C., Nouvion A.L., Breton V., Benlolo S., Demarte L., Turbide C., Brodt P., Ferri L., Beauchemin N. Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer. Oncogene 2012, http://dx.doi.og/10.1038/onc.2012.112.